Evidence map›Paper›PMID 38601144›Full record

ArticleFrontiers in immunology2024

Loss of TET2 increases B-1 cell number and IgM production while limiting CDR3 diversity.

Emily Dennis, Maria Murach, Cassidy M R Blackburn, Melissa Marshall, Katherine Root, Tanyaporn Pattarabanjird, Justine Deroissart, Loren D Erickson, Christoph J Binder, Stefan Bekiranov and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Emily DennisBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Maria MurachBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Cassidy M R BlackburnBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Melissa MarshallBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Katherine RootBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Tanyaporn PattarabanjirdBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Justine DeroissartDepartment for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Loren D EricksonBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Christoph J BinderDepartment for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Stefan BekiranovBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Coleen A McNamaraBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, United States.
Carter Center · USUniversity of Virginia · USMedical University of Vienna · AT

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosisP01HL136275 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Catherine C Hedrick · 2017 to 2026
$25.5M
BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6M
Id3 and VSMC in Murine and Human AtherosclerosisR01HL148109 · NHLBI · UNIVERSITY OF VIRGINIA · PI MCNAMARA, COLEEN A · 2019 to 2022
$2.7M
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosisR01HL141123 · NHLBI · UNIVERSITY OF VIRGINIA · PI MCNAMARA, COLEEN A · 2018 to 2022
$2.0M
NCI NIH HHS P30 CA044579NHLBI NIH HHS P01 HL136275NHLBI NIH HHS R01 HL141123NHLBI NIH HHS R01 HL148109NHLBI NIH HHS T32 HL007284
6 · The paper itself

Abstract

Recent studies have demonstrated a role for Ten-Eleven Translocation-2 (TET2), an epigenetic modulator, in regulating germinal center formation and plasma cell differentiation in B-2 cells, yet the role of TET2 in regulating B-1 cells is largely unknown. Here, B-1 cell subset numbers, IgM production, and gene expression were analyzed in mice with global knockout of TET2 compared to wildtype (WT) controls. Results revealed that TET2-KO mice had elevated numbers of B-1a and B-1b cells in their primary niche, the peritoneal cavity, as well as in the bone marrow (B-1a) and spleen (B-1b). Consistent with this finding, circulating IgM, but not IgG, was elevated in TET2-KO mice compared to WT. Analysis of bulk RNASeq of sort purified peritoneal B-1a and B-1b cells revealed reduced expression of heavy and light chain immunoglobulin genes, predominantly in B-1a cells from TET2-KO mice compared to WT controls. As expected, the expression of IgM transcripts was the most abundant isotype in B-1 cells. Yet, only in B-1a cells there was a significant increase in the proportion of IgM transcripts in TET2-KO mice compared to WT. Analysis of the CDR3 of the BCR revealed an increased abundance of replicated CDR3 sequences in B-1 cells from TET2-KO mice, which was more clearly pronounced in B-1a compared to B-1b cells. V-D-J usage and circos plot analysis of V-J combinations showed enhanced usage of V

Indexed as

B-Lymphocyte SubsetsAnimalsB-LymphocytesCell CountImmunoglobulin Light ChainsImmunoglobulin MMiceTranslocation, GeneticImmunoglobulin Light ChainsImmunoglobulin MB-1 cellsB cell receptor (BCR)complementarity-determining region-3 (CDR3)immunoglobulin M (IgM)innate B cellsnatural antibodies (Nab)ten-eleven translocation-2 (TET2)

Identifiers

PMID38601144
PMCPMC11004297
OpenAlexW4393231341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.